A randomized controlled trial of teriparatide for accelerating bone union and improving clinical outcomes in patients with pertrochanteric fracture fixation.

Tanavalee C, Ngarmukos S, Amarase C, Tantavisut S, Jaruthien N, Tanavalee A

Scientific reports3 Jun 2025Cited by 7 (Europe PMC)

PMID40461584PMCIDPMC12134263DOI10.1038/s41598-025-03720-2PepBankPUB-40461584

Summary

This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes. Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively. The primary outcome was the radiographic bone union. The secondary outcome was clinical results, including Harris hip scores (HHS) and performance-based tests evaluated at the postoperative 2nd, 4th, 6th, 12th, and 24th weeks, and spine and contralateral hip bone mass density (BMD), comparing admission and the 24th week. There were no statistically significant differences in baseline characteristics, including age, sex, fracture classification, affected side, HHS, BMD, and blood test results. The mean and standard deviation of radiographic bone union time of the teriparatide and the placebo groups were 7.44 ± 3.34 weeks and 10.56 ± 4.98 weeks, respectively, with significant differences (p, 0.0083). From the 6th week, both teriparatide and placebo groups had significantly improved HHS (p, 0.008 and 0.0205, respectively) and time up-and-go test (TUGT) (p, 0.0348 and 0.0237, respectively). In the 24th week, the five-time sit-to-stand test (5 × SST) of teriparatide and placebo groups was significantly improved (p, 0.0013 and 0.0412, respectively). However, there were no differences in HHS, TUGT and 5 × SST between groups at all follow-up time points. In the 24th week, the teriparatide group had less decrease in spine, femoral neck, and total hip BMD from baseline to the placebo group; however, these differences were insignificant. In conclusion, a 12-week teriparatide administration following intertrochanteric fracture fixation significantly shortened the fracture healing time. Although there were no differences in improved clinical outcomes, the teriparatide group had less decline in BMD at 24 weeks than the placebo group.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients after pertrochanteric fracture fixation, teriparatide shortened radiographic union time versus placebo.
In plain wordsAfter pertrochanteric fracture fixation, teriparatide shortened bone union time versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadiographic bone union time
Study
n = 50
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Union time mean
7.44 weeks
teriparatide
Union time SD
3.34 weeks
teriparatide
Union time mean
10.56 weeks
placebo
Union time SD
4.98 weeks
placebo
Source sentences
Summary
The mean and standard deviation of radiographic bone union time of the teriparatide and the placebo groups were 7.44 ± 3.34 weeks and 10.56 ± 4.98 weeks, respectively, with significant differences (p, 0.0083).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
Show in the study text Report a problemFND-4046158401
02HumanRandomized controlled trialEfficacy outcome
After fracture fixation, Harris hip scores did not differ between teriparatide and placebo at any follow-up.
In plain wordsAfter fracture fixation, hip scores did not differ between teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHarris hip score between groups
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, there were no differences in HHS, TUGT and 5 × SST between groups at all follow-up time points.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
Show in the study text Report a problemFND-4046158405
03HumanRandomized controlled trialEfficacy outcome
After fracture fixation, time up-and-go results did not differ between teriparatide and placebo at any follow-up.
In plain wordsAfter fracture fixation, time up-and-go results did not differ between teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTime up-and-go between groups
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, there were no differences in HHS, TUGT and 5 × SST between groups at all follow-up time points.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
Show in the study text Report a problemFND-4046158406
04HumanRandomized controlled trialEfficacy outcome
After fracture fixation, sit-to-stand results did not differ between teriparatide and placebo at any follow-up.
In plain wordsAfter fracture fixation, sit-to-stand results did not differ between teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSit-to-stand between groups
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
However, there were no differences in HHS, TUGT and 5 × SST between groups at all follow-up time points.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
Show in the study text Report a problemFND-4046158407
05HumanRandomized controlled trialEfficacy outcome
After fracture fixation, spine BMD declined less with teriparatide than placebo, but the difference was not significant.
In plain wordsAfter fracture fixation, spine bone density declined less with teriparatide than placebo, without a significant difference.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSpine BMD decline
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
In the 24th week, the teriparatide group had less decrease in spine, femoral neck, and total hip BMD from baseline to the placebo group; however, these differences were insignificant.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
Show in the study text Report a problemFND-4046158408
06HumanRandomized controlled trialEfficacy outcome
After fracture fixation, femoral neck BMD declined less with teriparatide than placebo, but the difference was not significant.
In plain wordsAfter fracture fixation, femoral neck bone density declined less with teriparatide than placebo, without a significant difference.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD decline
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
In the 24th week, the teriparatide group had less decrease in spine, femoral neck, and total hip BMD from baseline to the placebo group; however, these differences were insignificant.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
Show in the study text Report a problemFND-4046158409
07HumanRandomized controlled trialEfficacy outcome
After fracture fixation, total hip BMD declined less with teriparatide than placebo, but the difference was not significant.
In plain wordsAfter fracture fixation, total hip bone density declined less with teriparatide than placebo, without a significant difference.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD decline
Study
n = 50
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
In the 24th week, the teriparatide group had less decrease in spine, femoral neck, and total hip BMD from baseline to the placebo group; however, these differences were insignificant.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
Show in the study text Report a problemFND-4046158410

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
After fracture fixation, Harris hip scores improved from baseline in both teriparatide and placebo groups from the sixth week.
In plain wordsAfter fracture fixation, hip scores improved from baseline in both teriparatide and placebo groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHarris hip score change
Study
n = 50
Comparator
Baseline in both groups
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
From the 6th week, both teriparatide and placebo groups had significantly improved HHS (p, 0.008 and 0.0205, respectively) and time up-and-go test (TUGT) (p, 0.0348 and 0.0237, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-4046158402
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
After fracture fixation, time up-and-go performance improved from baseline in both teriparatide and placebo groups from the sixth week.
In plain wordsAfter fracture fixation, time up-and-go performance improved from baseline in both teriparatide and placebo groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedTime up-and-go change
Study
n = 50
Comparator
Baseline in both groups
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
From the 6th week, both teriparatide and placebo groups had significantly improved HHS (p, 0.008 and 0.0205, respectively) and time up-and-go test (TUGT) (p, 0.0348 and 0.0237, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-4046158403
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
After fracture fixation, sit-to-stand performance improved from baseline in both teriparatide and placebo groups at the 24th week.
In plain wordsAfter fracture fixation, sit-to-stand performance improved from baseline in both teriparatide and placebo groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedFive-time sit-to-stand change
Study
n = 50
Comparator
Baseline in both groups
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In the 24th week, the five-time sit-to-stand test (5 × SST) of teriparatide and placebo groups was significantly improved (p, 0.0013 and 0.0412, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective, double-blind, placebo-controlled, randomized trial evaluated the effects of teriparatide following pertrochanteric fracture fixation on bone healing and clinical outcomes.
Summary · context
Among 50 participants having fractures and undergoing surgical fixation, 25 were randomly assigned to each group to receive daily teriparatide or placebo for 12 weeks and were followed until 24 weeks postoperatively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-4046158404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.